Cookie use on MRCVSonline
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive all cookies.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Agreement to develop E. coli O157:H7 vaccine
Researchers at work on the project in the Roslin Institute
Collaborative research enters commercial phase

Roslin Technologies has signed an agreement with animal sciences research establishments Moredun Research Institute, Scotland’s Rural College and the Roslin Institute at the University of Edinburgh, to fund the commercial development of an E. coli O157:H7 vaccine for cattle, which it is claimed will prevent illness in humans.

E. coli O157:H7 is a pathogenic bacterium of cattle that can cause life-threatening food-borne illness in humans through the consumption of contaminated products, such as dairy products and meat. Despite efforts to reduce contamination of food, E. coli O157:H7 causes one to 10 cases per 100,000 people, with certain countries having clusters of more virulent strains – notably the UK, USA, Argentina and Sweden.
 
The experimental vaccine has been developed to limit E. coli O157:H7 shedding from – and transmission between – cattle. Although the bacteria do not harm cattle, farmers will be encouraged to vaccinate animals against infection with this new vaccine. Early results have indicated that this vaccine may be more effective than other previous attempts and have a greater impact in reducing human exposure and infection.

The project team has been led by Dr Simon Wheeler COO of Roslin Technologies, with significant input from the principal investigators, Professor David Gally from Roslin Institute and Dr Tom McNeilly from Moredun Research Institute, who have been doing the fundamental research necessary to really understand whether the vaccine works and the essential science behind it.

Under the new agreement, Roslin Technologies will perform a two-step validation trial from May  to September 2020 in Nebraska, USA. The field trials will examine ‘super-shedding’ in cattle to discover whether the vaccine prevents shedding of the bacteria and is viable for commercial use.
 
The background research was funded  in part by UK agencies Defra (Department for Environment, Food & Rural Affairs), BBSRC (Biotechnology and Biological Sciences Research Council, FSA/FSS (Food Standards Agency/Food Standards Scotland), and other commercial partners. This valuable contribution is recognised by the project team.

Become a member or log in to add this story to your CPD history

Do you know a practice wellbeing star?

News Story 1
 Has someone in your practice team gone above and beyond to make your workplace a positive one during the coronavirus pandemic? Then why not nominate them for a 2020 Practice Wellbeing Star!

The joint RCVS Mind Matters Initiative/SPVS Practice Wellbeing Star nominations recognise individuals who have held up morale during a time when practices are facing unprecedented staffing and financial issues.

Nominees receive a certificate in recognition of their colleagues' appreciation of their achievements and will be entered into the prize draw for a pair of tickets to attend the joint SPVS and Veterinary Management Group Congress in January 2021.

 

Click here for more...
News Shorts
WellVet reopens ticket sales to online conference platform

Following the success of its online conference, the organisers behind WellVet Weekend have re-opened ticket sales to allow new delegates to access session recordings and its online networking platform.

The day-long conference saw more than 360 veterinary professionals mix activity sessions with personal development CPD, all hosted within a virtual conference platform. Now, with more than 500 minutes of CPD available, the resource is being re-opened to allow full access to the session recordings until May 2021.

Sessions are aimed at providing delegates with a range of proactive wellbeing tools to explore to find ways of improving their mental and physical health. Tickets are limited in number and on sale at wellvet.co.uk until 30th August 2020.